|
19 Mar 2025 |
Astec Lifesciences
|
Consensus Share Price Target
|
685.00 |
1010.00 |
- |
47.45 |
hold
|
|
|
|
|
18 May 2023
|
Astec Lifesciences
|
ICICI Direct
|
685.00
|
1350.00
|
1500.55
(-54.35%)
|
Target met |
Sell
|
|
|
|
|
09 Feb 2023
|
Astec Lifesciences
|
ICICI Direct
|
685.00
|
1300.00
|
1432.20
(-52.17%)
|
Target met |
Sell
|
|
|
|
|
27 Jul 2022
|
Astec Lifesciences
|
ICICI Direct
|
685.00
|
2215.00
|
1797.95
(-61.90%)
|
Target met |
Buy
|
|
|
|
|
04 May 2022
|
Astec Lifesciences
|
ICICI Direct
|
685.00
|
2215.00
|
1852.40
(-63.02%)
|
Target met |
Buy
|
|
|
|
|
28 Oct 2021
|
Astec Lifesciences
|
ICICI Securities Limited
|
685.00
|
1575.00
|
1251.65
(-45.27%)
|
Target met |
Buy
|
|
|
|
|
07 May 2019
|
Astec Lifesciences
|
Motilal Oswal
|
685.00
|
609.00
|
495.90
(38.13%)
|
|
Buy
|
|
|
Revenue grew 12.5% YoY to segment (+22% YoY to INR8.3b). EBITDA margin shrank 60bp YoY to 5.6% 7 May 2019 lower employee cost and other expenses. EBITDA was flat YoY at INR749m 13%/3%/11% YoY to INR58.7b/INR4.6b/INR2.4b. animal feed segment in 4QFY19 drove EBIT margin expansion of 250bp QoQ to 5.5%. GOAGRO is planning for two product launches in the standalone crop protection business. In Astec Lifesciences, it has guided for revenue and EBITDA growth of 15% and 20%, respectively, in FY20. We note that 4Q is a seasonally weak quarter for the palm oil business, wherein GOAGRO reported an EBIT loss of INR1m (v/s a profit of INR40m in 4QFY18) due to higher depreciation and interest cost for its new processing plant. (i) GOAGRO will revisit merger initiation with Astec Lifesciences after a few quarters.
|